Australian biotechnology company Cartherics, which is developing immune cell therapies for cancer and other diseases, has been awarded a US$300,000 G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials.
Cartherics secures G-Rex grant to support its ‘in house’ manufacturing program
December 18, 2024 Australian BiotechLatest Video
New Stories
-
Make the institution and its nobility work for patients, not the other way around
January 16, 2025 - - Latest News -
Could this system's 'nobility' embrace a new idea, even if they recognised it?
January 15, 2025 - - Latest News -
Patients do not live their condition as aggregated economic models
January 14, 2025 - - Latest News -
Delays were the intended outcome, not an unintended consequence
January 13, 2025 - - Latest News -
Attitudes may have evolved, but the framework they created remains virtually unchanged
January 13, 2025 - - Latest News -
Boehringer Ingelheim's Auckland office leads sustainability in NZ pharma sector
January 10, 2025 - - Latest News -
Companies welcome November PBAC outcomes
December 23, 2024 - - Latest News